NASHUA, N.H., June 29, 2022 (GLOBE NEWSWIRE) —

iCAD, Inc.

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that leading radiologists will highlight clinical examples demonstrating the power of

ProFound AI

^®

Risk

in an upcoming webinar titled “ProFound AI Risk in the Real-World” on Monday, July 18 at 9 am PT/12 noon ET/6 pm CEST. Visit

this link

to register.

The latest installment of the Company’s recently launched “ProFound Insights, ProFound Impact” webinar series, the live event will be moderated by iCAD’s Product Director of AI Solutions, Andjela Azabagic, and will feature the following distinguished experts:

• Axel Gräwingholt, MD, Radiologie am Theater, Paderborn, Germany
• Mark Traill, MD, University of Michigan Health-West, Wyoming, Michigan

The event follows iCAD’s recent “

Risk Assessment Reimagined

” webinar, where these experts previewed case studies and joined in a roundtable discussion with a distinguished researcher from the Karolinska Institutet who assisted in the development of the ProFound AI Risk algorithm.

“We are delighted to have Dr. Traill and Dr. Gräwingholt return to our virtual stage for this encore event and clinical case study review,” said Ms. Azabagic, who also moderated the previous event. “The clinical cases already shared were compelling examples of the power of iCAD’s technology, and we look forward to taking a deeper dive as they share additional, real-world cases demonstrating how the ProFound AI

^®

Breast Health Suite can help radiologists personalize women’s breast cancer screening based on their short-term risk and find cancers earlier.”

Hear from the event’s featured experts:

“iCAD has been the leader in this space for a long time, and their technologies are the real deal. With iCAD’s suite of ProFound AI Breast Health Solutions, my cancer detection rate has increased, I am more productive than ever, and my stress level has decreased. This technology offers a real triple threat that is clinically proven to improve radiologists’ performance and enhance patient care.”

-Mark Traill, MD, University of Michigan Health-West, Wyoming, MI

“We have found iCAD’s ProFound AI Breast Health Solutions have offered significant value at my facility, as the technology has significantly improved our efficiency and cancer detection rates. These solutions are powerful tools that offer radiologists more insight into a woman’s individual case, improve confidence and help in clinical decision making.”

-Axel Gräwingholt, MD, Radiologie am Theater, Paderborn, Germany

iCAD’s “ProFound Insights, ProFound Impact” webinar series launched earlier this year, featuring distinguished clinical, IT and administrative experts, customer success stories and impactful case studies. Previous event recordings are available on the Company’s website,

www.icadmed.com

.

About iCAD, Inc.



Headquartered in Nashua, NH, iCAD

^®

is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit

www.icadmed.com

.

Forward-Looking Statements


Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expected benefits of ProFound AI

^®

, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Contact:

Media Inquiries:

Jessica Burns, iCAD

+1-201-423-4492

[email protected]

Investor Inquiries:

iCAD Investor Relations


[email protected]